Both STAG2 mutations and the expression of EWS-FLI1 fusion are frequently encountered in Ewing’s sarcoma and are likely an explanation to why this tumor type demonstrates an overall greater sensitivity to PARP inhibition compared to other pediatric tumor types. The gene discussed is PARP1; the disease is Ewing sarcoma.